AstraZeneca Pharma India has entered into agreement with AstraZeneca UK (AZ UK) pursuant to which the company would receive from AZ UK, the reimbursement of certain costs incurred for the marketing and promotion of the new launch products and support for the distribution of other products supplied by AZ UK, in accordance with the arm s length return on revenues.
Recently, AstraZeneca entered into five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
